EyeBio closed an extension to its Series A financing, ending with $130 million raised, according to a press release.
The proceeds will help accelerate the company’s clinical development program and build out its retina pipeline.
New investors included Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC, with participation from existing investors SV Health Investors, Jeito Capital, Samsara Biocapital and MRL Ventures Fund.
EyeBio also announced the completion of enrollment in the multiple ascending dose portion of the phase 1b/2a AMARONE clinical trial of Restoret in patients